Featured Research

from universities, journals, and other organizations

Topical Agent Found To Kill Papillomavirus

Date:
February 18, 1999
Source:
Penn State
Summary:
A common surfactant and detergent found in many shampoos and toothpastes is the first topical microbicidal agent shown to kill animal and human papillomavirus, according to a Penn State researcher.

HERSHEY, PA--A common surfactant and detergent found in many shampoos and toothpastes is the first topical microbicidal agent shown to kill animal and human papillomavirus, according to a Penn State researcher. Sodium dodecyl sulfate (SDS) was found in cell culture and animal testing to inactivate sexually transmitted viruses including human immunodeficiency virus (HIV), herpes simplex virus type 2 (HSV-2) and human papillomaviruses (HPVs). These viruses cause AIDS, genital herpes and genital warts, respectively.

Related Articles


"This is a major step toward our goal of producing a practical, non-toxic, inexpensive, discreet product which women can apply topically to the vagina prior to intercourse -- a product which would protect them from HPV infection even during encounters with infected partners," explains Mary K. Howett, Ph.D., professor of microbiology and immunology at Penn State's College of Medicine. "In the case of previously infected women, this agent could prevent them from transmitting the virus to their partners. In addition, this agent could be used alone or with other currently available microbicides or spermicides to prevent HSV-2 and HIV transmission."

Howett and her colleagues' work titled, "A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses," is published in the February issue of the journal Antimicrobial Agents and Chemotherapy.

Howett says it will take at least several years before such products will be produced for use in humans. However, she adds that such products could greatly reduce cervical cancer.

Protection from genital wart viruses is important to public health because lesions caused by these viruses can progress to cancer, most notably cancer of the uterine cervix. This cancer causes 5,000 deaths per year in women in the U.S. In the developing world, cervical cancer is the number one cause of cancer related deaths in women. Worldwide, 250,000 women die annually from this form of cancer. Prevention of HPV infection could prevent most of these cancers. HPV infection may also lead to other cancers in the ano-genital tracts of women and men. HPV is frequently associated with vulvar and anal cancers. Prevention from transmission could also protect men and women from development of these cancers.

It is thought that about one in four women are infected by these viruses in the genital tract, with 1 to 3 percent of women showing overt signs of clinical infection upon gynecologic examination. Although most infected people do not develop cancer, individuals with HPV worry about infecting their partners, suffer from physical repercussions including possible loss of fertility and fear the development of cancer. Many people with HPV infection are unaware that they are infected. HPV infections occur commonly in adolescents and in people during their reproductive years. Lesions caused by these viruses are worse in immunocompromised people such as those with AIDS.

Howett and her colleagues are searching for partners to develop products that incorporate these anti-papillomavirus agents, alone or in combination with other microbicides. One such partnership has been established with Dan Malamud, Ph.D., and investigators at Biosyn, Inc. in Philadelphia to include SDS in products containing C31G, another potent microbicide under development by Biosyn.

The findings presented in this paper result from joint research efforts by investigators in the Departments of Microbiology and Immunology and Pathology and the Jake Gittlen Cancer Research Institute at The Milton S. Hershey Medical Center of the Penn State College of Medicine in Hershey, Pa. and investigators in the Department of Biochemistry at the University of Pennsylvania School of Dental Medicine, and at Biosyn, Inc. in Philadelphia, Pa.

The work was performed through funding provided by a Program Project Grant that was awarded to Penn State, the University of Pennsylvania, Biosyn, Inc. and the University of North Carolina by the National Institute of Allergy and Infectious Diseases, and from support provided by the Jake Gittlen Cancer Research Institute.


Story Source:

The above story is based on materials provided by Penn State. Note: Materials may be edited for content and length.


Cite This Page:

Penn State. "Topical Agent Found To Kill Papillomavirus." ScienceDaily. ScienceDaily, 18 February 1999. <www.sciencedaily.com/releases/1999/02/990218070418.htm>.
Penn State. (1999, February 18). Topical Agent Found To Kill Papillomavirus. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/1999/02/990218070418.htm
Penn State. "Topical Agent Found To Kill Papillomavirus." ScienceDaily. www.sciencedaily.com/releases/1999/02/990218070418.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins